MX2019004602A - Agentes anti-proliferativos para tratar pah. - Google Patents
Agentes anti-proliferativos para tratar pah.Info
- Publication number
- MX2019004602A MX2019004602A MX2019004602A MX2019004602A MX2019004602A MX 2019004602 A MX2019004602 A MX 2019004602A MX 2019004602 A MX2019004602 A MX 2019004602A MX 2019004602 A MX2019004602 A MX 2019004602A MX 2019004602 A MX2019004602 A MX 2019004602A
- Authority
- MX
- Mexico
- Prior art keywords
- proliferative agents
- treating pah
- pulmonary
- hypertension
- pah
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960004390 palbociclib Drugs 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se puede tratar hipertension pulmonar y enfermedades relacionadas, como hipertension arterial pulmonar, al administrar una dosis efectiva de un inhibidor de CDK, incluyendo palbociclib, 6-acetil-8-ciclopentil-5-metil-2-{[5-(piperazin-1-il) piridin-2il]amino}pirido[2,3-d]pirimidin-7(8H)-ona, o sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410566P | 2016-10-20 | 2016-10-20 | |
| US201762548629P | 2017-08-22 | 2017-08-22 | |
| PCT/IB2017/056226 WO2018073687A1 (en) | 2016-10-20 | 2017-10-09 | Anti-proliferative agents for treating pah |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004602A true MX2019004602A (es) | 2019-06-17 |
Family
ID=60138667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004602A MX2019004602A (es) | 2016-10-20 | 2017-10-09 | Agentes anti-proliferativos para tratar pah. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10849903B2 (es) |
| EP (2) | EP3528812B1 (es) |
| JP (2) | JP2018076290A (es) |
| KR (1) | KR20190071763A (es) |
| CN (1) | CN109843297A (es) |
| AU (1) | AU2017345367A1 (es) |
| BR (1) | BR112019005526A2 (es) |
| CA (1) | CA3040815C (es) |
| ES (2) | ES2934846T3 (es) |
| IL (1) | IL266026A (es) |
| MX (1) | MX2019004602A (es) |
| RU (1) | RU2019111887A (es) |
| SG (1) | SG11201902523UA (es) |
| TW (1) | TWI656876B (es) |
| WO (1) | WO2018073687A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022529930A (ja) | 2019-04-19 | 2022-06-27 | ファイザー・インク | Ｐａｈを処置するための抗増殖薬 |
| TWI769382B (zh) * | 2019-06-21 | 2022-07-01 | 長庚大學 | 利博西林用於製備治療罹患磷酸二酯酶４介導疾病的患者的醫藥組合物及用途 |
| CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI224966B (en) | 1999-11-02 | 2004-12-11 | Pfizer | Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient |
| EP1280789A1 (en) | 2000-05-03 | 2003-02-05 | LG Life Sciences Ltd. | Cdk inhibitors having 3-hydroxychromen-4-one structure |
| BR122016021801B8 (pt) | 2002-01-22 | 2021-05-25 | Warner Lambert Co | compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| DK1648889T3 (da) | 2003-07-11 | 2009-01-05 | Warner Lambert Co | Isethionatsalt af en selektiv CDK4-inhibitor |
| AU2006205851A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| JO3235B1 (ar) * | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| CA2662768A1 (en) | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| PL2091537T3 (pl) * | 2006-11-23 | 2013-10-31 | Sinoxa Pharma Gmbh | Kompozycja farmaceutyczna do leczenia arteriopatii włośniczkowej |
| AU2008309517B2 (en) * | 2007-10-12 | 2013-03-14 | Astrazeneca Ab | Inhibitors of protein kinases |
| WO2009121031A1 (en) * | 2008-03-27 | 2009-10-01 | Vascular Biosciences, Inc. | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases |
| WO2010000913A1 (en) | 2008-07-04 | 2010-01-07 | Lauri Ilmari Pekansaari | Sauna oven center boiler |
| AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| CA2734802C (en) | 2008-08-22 | 2016-05-31 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| WO2011026911A1 (en) | 2009-09-04 | 2011-03-10 | Novartis Ag | Bipyridines useful for the treatment of proliferative diseases |
| IN2012DN01273A (es) | 2009-09-04 | 2015-05-15 | Novartis Ag | |
| WO2011083387A1 (en) * | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| HUE030714T2 (en) | 2010-10-25 | 2017-05-29 | G1 Therapeutics Inc | Cdk inhibitors |
| RU2013127655A (ru) | 2010-11-19 | 2014-12-27 | Пирамал Энтерпрайзис Лимитед | Фармацевтическая комбинация паклитаксела и ингибитора cdk |
| SI3431475T1 (sl) * | 2013-02-21 | 2021-08-31 | Pfizer Inc. | Trdne oblike selektivnega zaviralca CDK4/6 |
| AU2015243585B2 (en) | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
| WO2016015604A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| CN105294682B (zh) | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| WO2016053040A1 (ko) | 2014-10-02 | 2016-04-07 | 주식회사 엘지화학 | 리튬 이차 전지용 전해액 첨가제, 상기 전해액 첨가제를 포함하는 비수성 전해액 및 리튬 이차 전지 |
| CN104758292B (zh) * | 2015-03-06 | 2018-05-01 | 天津医科大学总医院 | Pd-0332991在制备防治耐药肿瘤药物的用途 |
| EP3277673B1 (en) * | 2015-04-01 | 2022-05-04 | Rigel Pharmaceuticals, Inc. | Tgf-beta inhibitors |
-
2017
- 2017-10-09 WO PCT/IB2017/056226 patent/WO2018073687A1/en not_active Ceased
- 2017-10-09 BR BR112019005526A patent/BR112019005526A2/pt not_active Application Discontinuation
- 2017-10-09 CN CN201780064690.9A patent/CN109843297A/zh active Pending
- 2017-10-09 ES ES20203847T patent/ES2934846T3/es active Active
- 2017-10-09 KR KR1020197014211A patent/KR20190071763A/ko not_active Ceased
- 2017-10-09 EP EP17787029.2A patent/EP3528812B1/en not_active Not-in-force
- 2017-10-09 SG SG11201902523UA patent/SG11201902523UA/en unknown
- 2017-10-09 US US16/343,566 patent/US10849903B2/en not_active Expired - Fee Related
- 2017-10-09 ES ES17787029T patent/ES2852349T3/es active Active
- 2017-10-09 RU RU2019111887A patent/RU2019111887A/ru not_active Application Discontinuation
- 2017-10-09 CA CA3040815A patent/CA3040815C/en active Active
- 2017-10-09 AU AU2017345367A patent/AU2017345367A1/en not_active Abandoned
- 2017-10-09 EP EP20203847.7A patent/EP3804724B1/en active Active
- 2017-10-09 MX MX2019004602A patent/MX2019004602A/es unknown
- 2017-10-17 TW TW106135422A patent/TWI656876B/zh not_active IP Right Cessation
- 2017-10-18 JP JP2017201576A patent/JP2018076290A/ja active Pending
-
2019
- 2019-04-14 IL IL266026A patent/IL266026A/en unknown
-
2020
- 2020-11-04 US US17/089,154 patent/US11439646B2/en active Active
- 2020-12-01 JP JP2020199659A patent/JP2021038265A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL266026A (en) | 2019-06-30 |
| SG11201902523UA (en) | 2019-05-30 |
| US20190240226A1 (en) | 2019-08-08 |
| EP3528812B1 (en) | 2020-12-30 |
| US11439646B2 (en) | 2022-09-13 |
| AU2017345367A1 (en) | 2019-04-04 |
| TWI656876B (zh) | 2019-04-21 |
| EP3804724A1 (en) | 2021-04-14 |
| CA3040815C (en) | 2021-07-20 |
| CA3040815A1 (en) | 2018-04-26 |
| US20210186974A1 (en) | 2021-06-24 |
| CN109843297A (zh) | 2019-06-04 |
| RU2019111887A (ru) | 2020-11-20 |
| US10849903B2 (en) | 2020-12-01 |
| ES2852349T3 (es) | 2021-09-13 |
| RU2019111887A3 (es) | 2020-11-20 |
| EP3528812A1 (en) | 2019-08-28 |
| EP3804724B1 (en) | 2022-12-07 |
| BR112019005526A2 (pt) | 2019-06-18 |
| JP2018076290A (ja) | 2018-05-17 |
| KR20190071763A (ko) | 2019-06-24 |
| TW201827054A (zh) | 2018-08-01 |
| WO2018073687A1 (en) | 2018-04-26 |
| ES2934846T3 (es) | 2023-02-27 |
| JP2021038265A (ja) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519401541B1 (ar) | [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات | |
| MX2021002321A (es) | Nuevos metodos. | |
| PH12019500776A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2021002322A (es) | Nuevos metodos. | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2021006901A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| EP4353747A3 (en) | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer | |
| MX2018012165A (es) | Metodos de tratamiento de canceres pediatricos. | |
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12018502297A1 (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| JOP20220042A1 (ar) | طرق لعلاج فرط فينيل ألانين الدم | |
| NZ754944A (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
| MX2019004602A (es) | Agentes anti-proliferativos para tratar pah. | |
| WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
| MX373272B (es) | Terapia de combinacion. | |
| NZ757557A (en) | Methods of preventing or treating ophthalmic diseases | |
| MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
| EA201992414A1 (ru) | Комбинация nk1-антагониста и способ лечения синуклеинопатий | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MY203494A (en) | 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. |